Circulation Cardiovascular Interventions · 2022 · 68 citations · 27 references
MedicineCardiologyPharmacologyClinical CardiologyClinical PharmacologyInterventional CardiologyAntiplatelet TherapyCoronary Artery DiseasePercutaneous Coronary InterventionThrombosisThrombosis ManagementThrombosis PreventionBleeding Risk ReductionClinical Outcomes After Percutaneous Coronary InterventionHigh-risk Percutaneous Coronary InterventionNoninferiority Trial Sample SizeNoninferiority TrialsSerious Adverse EventsStent Thrombosis PreventionThrombotic Risk Reduction
Background: Patients at high-bleeding risk (HBR) undergoing percutaneous coronary intervention represent a challenging patient population. The use of drug-coated balloon (DCB) allows shorter duration of dual antiplatelet therapy compared with drug-eluting stents (DES) and reduces thrombotic risk due to the absence of a permanent implant. The present analysis aimed to investigate if the effect of DCB versus DES differed between patients with and without HBR treated with percutaneous coronary intervention in small coronary arteries. Methods: This prespecified subgroup analysis of a multicenter, randomized, noninferiority trial included 758 patients with de novo lesions in coronary vessels <3 mm and an indication for percutaneous coronary intervention, randomized to DCB (n=382) or second-generation DES (n=376). Patients were followed over 3 years for major adverse cardiac events. Results: Of the 758 patients randomized, 155 (20%) had HBR; these patients had higher mortality at 3 years (hazard ratio [95% CI], 3.09 [1.78–5.36]; P <0.001). Rates of major bleeding events were overall low but tended to be lower after DCB versus DES (1.6% versus 3.7%; P =0.064), were similar in patients with HBR (4.5% versus 3.4%) but less frequent in DCB-versus DES-treated patients without HBR (0.9% versus 3.8%). There was no difference in major adverse cardiac events between DCB and DES regardless of bleeding risk (HBR, hazard ratio: 1.16 [0.51–2.62]; P =0.719 versus non-HBR, 0.96 [0.62–1.49]; P =0.863). Conclusions: DCBs were similarly safe and effective as current-generation DES in the treatment of coronary arteries <3 mm, regardless of bleeding risk. In patients treated with DCB, there was a trend towards a reduction of severe bleeding events at 3 years. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01574534.
27
R: A Language and Environment for Statistical Computing
R Core Team · 2000 · 353K citations · Full text
Natural Sciences, Computer Science, Statistical Computing +10
Gerhard Hindricks, Tatjana Potpara, Nikolaos Dagres et al. · European Heart Journal · 2020 · 9.9K citations · Full text
2018 ESC/EACTS Guidelines on myocardial revascularization
Franz‐Josef Neumann, Miguel Sousa‐Uva, Anders Ahlsson et al. · European Heart Journal · 2018 · 7.1K citations · Full text
Clinical End Points in Coronary Stent Trials
Donald E. Cutlip, Stephan Windecker, Roxana Mehran et al. · Circulation · 2007 · 5.4K citations
Standardized Bleeding Definitions for Cardiovascular Clinical Trials
Roxana Mehran, Sunil V. Rao, Deepak L. Bhatt et al. · Circulation · 2011 · 4.4K citations
Medicine, Cardiology, Hematology +10